EUVIMEDEUVIMED entdecken
Crossref

PMEPA1 promotes mTOR inhibitor resistance in triple-negative breast cancer: Targeting the TGF-β/PMEPA1 axis as a therapeutic strategy to overcome resistance

M S Chithra Pournami, Biswajit Biswas, Sai Balaji Andugulpati, Yogesh Chandra, Ramesh Ummanni

Biochemical Pharmacology · 2026-07 · 249 · 117889

DOI: 10.1016/j.bcp.2026.117889 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Biochemical Pharmacology, 2026-07. Verfasst von M S Chithra Pournami und 4 weiteren Autor:innen. Beteiligte Einrichtung: Department of Applied Biology, CSIR - Indian Institute of Chemical Technology (CSIR-IICT), Hyderabad 500 007, India; Academy of Scientific & Innovati…. Hauptthemen laut MEDLINE: Triple Negative Breast Neoplasms, Drug Resistance, Neoplasm, Transforming Growth Factor beta, MTOR Inhibitors. Die Arbeit nennt 52 Literaturangaben. Gefördert von: Indian Council of Medical Research, Department of Biotechnology, Ministry of Science and Technology, India, Council of Scientific and Industrial Research, India.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Acquired resistance to mammalian target of rapamycin inhibitors (mTORi) severely limits their clinical efficacy in triple-negative breast cancer (TNBC), a subtype devoid of targeted therapeutic options. To model acquired resistance, we established two mTORi-resistant TNBC cell lines, MDA-MB-231/DREVE and MDA-MB-231/DRRIDA through chronic exposure to everolimus and ridaforolimus, respectively. These resistant cells exhibited sustained mTOR signaling, evasion of G1 arrest, enhanced migratory potential, and anchorage-independent growth. Transcriptome profiling by whole RNA sequencing combined with GSEA analyses, revealed convergent activation of the PI3K/AKT axis and concomitant upregulation of TGF-β and KRAS signaling alongside suppression of IL-2-mediated responses. Integrative analysis identified PMEPA1, a well-characterized modulator of TGF-β signaling, as a key driver of resistance. PMEPA1 expression was markedly elevated in resistant cells and correlated with poor survival in TNBC patients. We demonstrated that PMEPA1 confers resistance to mTORi by attenuating canonical SMAD signaling while promoting activation of the PI3K/AKT/mTOR pathway through PTEN downregulation. Targeted silencing of PMEPA1 restored drug sensitivity, reversed EMT and attenuated stem-like properties. Pharmacological inhibition of upstream TGF-β signaling with galunisertib suppressed PMEPA1 and synergistically restored sensitivity to mTORi in both invitro and xenograft models, resulting insignificant tumor regression. Histopathological analyses revealed reduced cellular proliferation, angiogenesis, and PMEPA1 expression, accompanied by increased necrotic areas in combination treatment. Collectively, these findings establish PMEPA1 as a dual modulator of canonical and non-canonical TGF-β signaling and a critical mediator of mTORi resistance in TNBC. Targeting the TGF-β/PMEPA1 axis represents a promising strategy to overcome resistance and improve clinical outcomes in mTORi-refractory TNBC.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Triple Negative Breast NeoplasmsDrug Resistance, NeoplasmTransforming Growth Factor betaMTOR InhibitorsMembrane ProteinsTOR Serine-Threonine KinasesHumansFemaleAnimalsMiceMDA-MB-231 CellsXenograft Model Antitumor AssaysCell Line, TumorSignal TransductionEverolimusMice, Nude

Stichwörter der Autor:innen

Breast CancerDrug resistanceEverolimusRidaforolimusmTOR pathway and TGF-β signaling

Substanzen

Transforming Growth Factor betaMTOR InhibitorsPMEPA1 protein, humanMembrane ProteinsTOR Serine-Threonine KinasesMTOR protein, humanEverolimus

Autor:innen und Institutionen

  • Department of Applied Biology, CSIR - Indian Institute of Chemical Technology (CSIR-IICT), Hyderabad 500 007, India; Academy of Scientific & Innovative Research, Ghaziabad 201002, India.
  • Department of Applied Biology, CSIR - Indian Institute of Chemical Technology (CSIR-IICT), Hyderabad 500 007, India; Academy of Scientific & Innovative Research, Ghaziabad 201002, India. Electronic address: ummanni@iict…

Förderung

  • Indian Council of Medical Research
  • Department of Biotechnology, Ministry of Science and Technology, India
  • Council of Scientific and Industrial Research, India

Zitieren

APA

Chithra Pournami, M. S., Biswas, B., Andugulpati, S. B., Chandra, Y., & Ummanni, R. (2026). PMEPA1 promotes mTOR inhibitor resistance in triple-negative breast cancer: Targeting the TGF-β/PMEPA1 axis as a therapeutic strategy to overcome resistance. Biochemical Pharmacology, 249, 117889. https://doi.org/10.1016/j.bcp.2026.117889

Vancouver

Chithra Pournami MS, Biswas B, Andugulpati SB, Chandra Y, Ummanni R. PMEPA1 promotes mTOR inhibitor resistance in triple-negative breast cancer: Targeting the TGF-β/PMEPA1 axis as a therapeutic strategy to overcome resistance. Biochemical Pharmacology. 2026;249:117889. doi:10.1016/j.bcp.2026.117889

BibTeX
@article{ChithraPournami2026,
  author = {Chithra Pournami, M S and Biswas, Biswajit and Andugulpati, Sai Balaji and Chandra, Yogesh and Ummanni, Ramesh},
  title = {PMEPA1 promotes mTOR inhibitor resistance in triple-negative breast cancer: Targeting the TGF-β/PMEPA1 axis as a therapeutic strategy to overcome resistance},
  journal = {Biochemical Pharmacology},
  year = {2026},
  volume = {249},
  pages = {117889},
  doi = {10.1016/j.bcp.2026.117889}
}
Kostenlos starten →